An Introduction to Melanoma
The past decade has seen significant advances in the treatment landscape of melanoma. Therapies targeting the BRAF oncoprotein pathway and the development of immunotherapies have transformed the standard of care for patients.
Expert video highlights and insights from the conference hub and comprehensive peer-reviewed articles from our journal portfolio provide updates on the changing treatment landscape. To learn more about how the latest developments impact on patient outcomes view our expert-led learning activities.
Georgina Long, ESMO 2022: Highlights in melanoma – SWOG S1801 trial investigating neoadjuvant versus adjuvant pembrolizumab for resected stage III-IV melanoma
Prof. Georgina Long (Melanoma Institute Australia, Wollstonecraft, Australia) joins touchONCOLOGY to discuss clinical trial highlights in melanoma presented at EMSO 2022. She highlights the SWOG S1801 trial, investigating neoadjuvant versus adjuvant pembrolizumab for resected stage III-IV melanoma, concluding use of a single-agent pembrolizumab, neoadjuvant therapy improves event-free survival compared to adjuvant therapy in high-risk resectable […]
Georgina Long, ESMO 2022: CheckMate 915 study – The use of ctDNA as a biomarker for predicting outcomes for adjuvant melanoma
In patients with resectable melanoma, circulating tumor DNA (ctDNA) detection post-resection may be useful to inform disease state and recurrence risk. Prof. Georgina Long (Melanoma Institute Australia, Wollstonecraft, Australia) joins touchONCOLOGY to discuss CheckMate 915 study and what it taught us about the use of nivolumab plus ipilumab in the adjuvant treatment of melanoma, and […]
Recognizing mycosis fungoides, a heterogeneous and challenging cutaneous T-cell lymphoma
Watch this activity to learn more about mycosis fungoides cutaneous T-cell lymphoma (MF-CTCL) and a new MF-CTCL online resource. Visit MF-Talks for more information.
Optimizing the patient journey in CSCC through multidisciplinary collaboration
In this activity, leading experts discuss optimal approaches for the management of patients with CSCC and consider how effective multidisciplinary collaboration can contribute to improved outcomes.
- Define multidisciplinary best practices for diagnostic workup of cutaneous squamous cell carcinoma (CSCC) and identification of risk factors influencing prognosis
- Outline interdisciplinary eligibility criteria for surgery and radiotherapy in patients with CSCC
- Determine the optimal use of systemic therapies in patients with unresectable locally advanced or metastatic CSCC and the role of the multidisciplinary tumour board in sharing clinical decisions in cancer care
Lymphocyte-activation Gene 3 and Programmed Cell Death 1 Checkpoint Inhibition as a Novel Combination in Advanced Melanoma
touchREVIEWS in Oncology & Haematology. 2021;17(2):58–9 DOI: https://doi.org/10.17925/OHR.2021.17.2.58
RELATIVITY-047 reported on the initial efficacy and safety of relatlimab (RELA), an antibody to lymphocyte-activating gene 3 (LAG-3), in combination with nivolumab (NIVO), an antibody to programmed cell death 1 (PD-1).1 These positive findings add to the existing evidence for the efficacy of anti-PD-1 therapy – either alone or in combination with ipilimumab (IPI), an antibody […]
Navigating the emerging complexities of melanoma treatment: New insights for clinical practice
Watch leading experts discuss evolving neoadjuvant, adjuvant and metastatic treatment options for patients with melanoma, taking in the latest data presented at the ESMO Congress 2021.
- Describe the long-term survival results in patients with melanoma and their relevance to treatment decisions
- Evaluate current strategies to improve outcomes for patients with melanoma who do not experience a durable response
- Recall the latest data for emerging treatment options, including the use of triple combination approaches, and how these therapies fit into the melanoma treatment paradigm
Jason Luke, ESMO 2021: Efficacy and Safety Results from the KEYNOTE-716 Double-blind Phase III Trial
touchONCOLOGY joins Dr Jason Luke (UPMC Hillman Cancer Center, PA, USA) at ESMO 2021 to discuss the efficacy and safety results from the KEYNOTE-716 double-blind phase III trial. Questions 1. Patients with high-risk stage II melanoma are at significant risk of recurrence after surgical resection – what treatment options do these patients currently have to […]
Immunotherapy and evolving approaches for basal cell carcinoma
Watch leading experts discuss evolving treatment options for patients with advanced basal cell carcinoma, and how novel immunotherapeutic approaches within the emerging clinical study landscape may improve patient care.
- Recognize the current unmet needs and rationale for alternative treatment options for patients with basal cell carcinoma (BCC)
- Evaluate the latest data for using immunotherapy to treat patients with advanced BCC
- Define how the latest advances in BCC may impact clinical practice
Evan Lipson, ASCO 2021: Relatlimab plus Nivolumab in Advanced Melanoma
TouchONCOLOGY got the chance to catch up with Dr Evan Lipson (Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA) around the RELATIVITY-047 study, which investigated the combined therapy of relatlimab plus nivolumab in patients with advanced melanoma. The abstract ‘Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma: Primary phase III […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!